Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
Laurent Peyrin‐Biroulet(Délégation Centre-Est), Toshimitsu Fujii(Goethe University Frankfurt), Cheng‐Tang Chiu(Chang Gung University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Monika Augustyn, William J. Sandborn(University of San Diego), Rafał Filip(University of Rzeszów), Tadakazu Hisamatsu(Kyorin University), П. С. Андреев, Julián Panés(Hospital Clínic de Barcelona), Axel Dignaß(Goethe University Frankfurt), Chou‐Chen Chen(Janssen (United States)), Olena Datsenko, Jakob Begun, Lilia Aitova, Brian G. Feagan(Western University), David T. Rubin(University of California System), Pieter Dewint(GZA Ziekenhuizen Campus Sint-Augustinus), Rebbecca Wilson(Janssen (United States)), Chang Hwan Choi(Chung-Ang University), Brian Bressler(University of British Columbia), Jessica R. Allegretti(Brigham and Women's Hospital), Eugeni Domènech(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Elena Bunkova, Chou-Pin Chen(Janssen (United States)), George Duvall, Paola Balestrieri, Flavio Caprioli(University of Rome Tor Vergata), Ronald Fogel(Henry Ford Health System), Joris Dutré(Goethe University Frankfurt), Engin Altıntaş, Romain Altwegg(Université de Montpellier), Michele Cicala(Università Campus Bio-Medico), Nicole Shipitofsky(Janssen (United States)), Halyna Afanasieva, Kuan‐Hsiang Gary Huang(Janssen (United States)), Sharyle Fowler(Massachusetts General Hospital), Rute Cerqueira(Icahn School of Medicine at Mount Sinai), Luciana Soledad Brunatto(Western University), Diego Bulgheroni(Western University), Qian Cao(Sir Run Run Shaw Hospital), Mercedes Cabello(Hospital Regional Universitario de Málaga), О. Аbrahamovych, Kazuki Aomatsu, J. C. Fernández(Goethe University Frankfurt), Gary R. Lichtenstein(University of Pennsylvania), Hongyan Zhang(Northwest A&F University), Chenglong Han(Janssen (United States)), Baili Chen(Sun Yat-sen University), Matthew Germinaro(Johnson & Johnson (United States))
Cited by 97
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k